Cargando…

Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2

Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4(+) and CD8(+) T-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casado, José L., Vizcarra, Pilar, Haemmerle, Johannes, Velasco, Héctor, Martín-Hondarza, Adrián, Rodríguez-Domínguez, Mario J., Velasco, Tamara, Martín, Sara, Romero-Hernández, Beatriz, Fernández-Escribano, Marina, Vallejo, Alejandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Short communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057925/ https://www.ncbi.nlm.nih.gov/pubmed/35529539 http://dx.doi.org/10.1016/j.jvacx.2022.100165

Ejemplares similares

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Impact of SARS-CoV-2-specific memory B cells on the immune response after mRNA-based Comirnaty vaccine in seronegative health care workers
por: Vallejo, Alejandro, et al.
Publicado: (2022)

Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity
por: Vallejo, Alejandro, et al.
Publicado: (2022)

SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study
por: Casado, José L., et al.
Publicado: (2021)

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity
por: Casado, Jose L, et al.
Publicado: (2021)

Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination
por: Casado, José L., et al.
Publicado: (2023)

Expansion of CD56(dim)CD16(neg) NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients
por: Casado, José L., et al.
Publicado: (2021)

mRNA-based SARS-CoV-2 Comirnaty vaccine elicits weak and short specific memory B cell response in individuals with no previous infection
por: Casado, José L., et al.
Publicado: (2023)

Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination
por: Casado, José L., et al.
Publicado: (2022)

Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice
por: Garcia-Dominguez, Dario, et al.
Publicado: (2022)

Pre-existing immunity modulates responses to mRNA boosters
por: Dangi, Tanushree, et al.
Publicado: (2022)

Pre-existing immunity modulates responses to mRNA boosters
por: Dangi, Tanushree, et al.
Publicado: (2023)

The circadian clock in immune cells controls the magnitude of Leishmania parasite infection
por: Kiessling, Silke, et al.
Publicado: (2017)

Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults
por: Brockman, Mark A, et al.
Publicado: (2021)

Rank distributions: Frequency vs. magnitude
por: Velarde, Carlos, et al.
Publicado: (2017)

Programming the magnitude and persistence of antibody responses with innate immunity
por: Kasturi, Sudhir Pai, et al.
Publicado: (2011)

Adaptive immunity to human coronaviruses is widespread but low in magnitude
por: Tan, Hyon‐Xhi, et al.
Publicado: (2021)

DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques
por: Jalah, Rashmi, et al.
Publicado: (2014)

INFLUENCE OF GENETIC FACTORS ON THE MAGNITUDE AND THE HETEROGENEITY OF THE IMMUNE RESPONSE IN THE RABBIT
por: Eichmann, Klaus, et al.
Publicado: (1971)

Contribution of Evolutionary Selected Immune Gene Polymorphism to Immune-Related Disorders: The Case of Lymphocyte Scavenger Receptors CD5 and CD6
por: Casadó-Llombart, Sergi, et al.
Publicado: (2021)

DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response
por: Petkov, Stefan, et al.
Publicado: (2018)

Schedule and magnitude of reproductive investment under immune trade-offs explains sex differences in immunity
por: Metcalf, C. Jessica E., et al.
Publicado: (2018)

Trabecular Bone Adaptation to Low-Magnitude High-Frequency Loading in Microgravity
por: Torcasio, Antonia, et al.
Publicado: (2014)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Correction: DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response
por: Petkov, Stefan, et al.
Publicado: (2021)

Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
por: Casado, José L., et al.
Publicado: (2022)

Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors
por: Saavedra, Cristina, et al.
Publicado: (2023)

Does Herd Immunity Exist in Aquatic Animals?
por: Standish, Isaac F., et al.
Publicado: (2016)

Study of humoral and cellular immunity in vaccinated with mRNA‐1273
por: Gutiérrez‐Bautista, Juan Francisco, et al.
Publicado: (2022)

Scope and magnitude of private sector financing and provision of immunization in Benin, Malawi and Georgia
por: Levin, Ann, et al.
Publicado: (2019)

The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
por: Tejedor Vaquero, Sonia, et al.
Publicado: (2021)

Enhancement of Implant Osseointegration by High-Frequency Low-Magnitude Loading
por: Zhang, Xiaolei, et al.
Publicado: (2012)

Magnitude of the contralateral efferent olivocochlear effect as a function of the frequency
por: Miranda, Fernanda Anza, et al.
Publicado: (2022)

Low risk of bacterial co-infection, opportunistic diseases, and persistent immunosuppression in people living with HIV and COVID-19
por: Casado, José L., et al.
Publicado: (2022)

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments
por: Cortés, Alfonso, et al.
Publicado: (2022)

MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine
por: Boulouis, Caroline, et al.
Publicado: (2022)

Pre‐existing heterologous T‐cell immunity and neoantigen immunogenicity
por: Leng, Qibin, et al.
Publicado: (2020)

Milder disease with Omicron: is it the virus or the pre-existing immunity?
por: Sigal, Alex
Publicado: (2022)

Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?
por: Fausther-Bovendo, Hugues, et al.
Publicado: (2014)

Foxo3 controls the magnitude of T cell immune responses by modulating dendritic cell function
por: Dejean, Anne S., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_8e0ntabpl5nquj0994hf1jomjn